Lyell Immunopharma, Inc.
Ticker: LYEL
| Insider | Title |
|---|---|
| Cathy Friedman | Director |
| Charles W. Newton | Chief Financial Officer |
| Clinton Bybee | 10% or greater ownership |
| Elizabeth G Nabel | Director |
| Elizabeth Homans | Chief Executive Officer, Director |
| Gary K. Lee | Chief Scientific Officer |
| Hans Edgar Bishop | Director |
| Heather D Turner | Chief General Counsel |
| Keith Crandell | 10% or greater ownership |
| Lynn Seely | President and CEO, Director |
| Matthew Lang | Chief Business Officer |
| Otis W Brawley | Director |
| Plc Glaxosmithkline | 10% or greater ownership |
| Rahsaan Thompson | Chief Legal Officer |
| Richard Klausner | Director |
| Robert Nelsen | Director, 10% or greater ownership |
| Stephen J. Hill | Chief Operating Officer |
| Sumant Ramachandra | Director |
| Tina M. Albertson | Chief Medical Officer |
| Venture Fund Ix Overage, L.p. Arch | 10% or greater ownership |
| Venture Fund Ix, L.p. Arch | 10% or greater ownership |
| Venture Partners Ix Overage, L.p. Arch | 10% or greater ownership |
| Venture Partners Ix, L.p. Arch | 10% or greater ownership |
| Venture Partners Ix, Llc Arch | 10% or greater ownership |
| William Jl Rieflin | Director |